Exclusive: Inside the facilities making the world’s most prevalent COVID-19 vaccine https://ti.me/3grX0v9
The risk of dying from COVID is much higher than getting a blood clot from a vaccine. But even more concerning is a new report from Oxford University that shows catching the coronavirus puts you at even more risk of a deadly blood clot. Each delay puts more lives at risk, as the coronavirus spreads. It’s a balancing act between speed and caution in the fight against COVID-19.
The rollout of the Johnson & Johnson vaccine has been paused in the US, Europe and South Africa after reports of rare blood clotting in a very small number of people. Health authorities said they were halting the use of the shot while they investigate the cases — and that they were doing this out of “an abundance of caution.” The Astra Zeneca jab was also recently temporarily suspended in some countries after being linked to rare blood clots. Authorities are calling it a short “pause.” The US’s Johnson and Johnson vaccine has hit the same stumbling block as the UK’s AstraZeneca jab did last month: a likely link to a rare and deadly blood clot. Use of Johnson and Johnson’s Janssen vaccine has now been halted across the US, Europe and South Africa, with health authorities investigating six incidents of clotting in younger women, one of them fatal. The US-developed vaccine uses an adenovirus to trigger immunity – the same mechanism as the UK’s AstraZeneca vaccine. It accounts for roughly 5 percent of vaccines delivered so far in the US. This is a setback to Europe, too. Johnson and Johnson announced it will delay it’s rollout on the continent. The company had already started processing an order from the EU of 200 million doses. The Janssen jab has been partially rolled out in Africa, where a majority of countries don’t have enough vaccines even for their healthcare workers. The African Union signed a deal for 220 million doses this year. But US authorities remain hopeful. They’re saying it could only be a matter of days before the rollout resumes.
A new study by a team from the University of Michigan Institute for Healthcare Policy and Innovation shows that adults over age 50 place more importance on convenience-related factors, rather than reputation, when choosing a doctor.
The study, based on data from IHPI’s National Poll on Healthy Aging supported by AARP and Michigan Medicine, still shows that online ratings and reviews of physicians play an important role, and should receive attention from providers and policymakers.
Dr. Jeffrey Kullgren, a U-M primary care physician and lead author of the study, describes the findings.
Remember the first COVID-19 vaccine jabs? They gave us hope that life might return to what it was before the pandemic. If we could only get enough people vaccinated. But some of the nations leading the world in vaccinations are still struggling with the coronavirus.
The virus that causes COVID-19 is mutating. Here is what you should know if you want to understand how variants are (and aren’t) complicating the pandemic.
Learn more at: https://gatesnot.es/3sP668R.SHOW LESS